That's a great question. Thank you.
In general, in genomics research there's a huge amount of data being created. There's a big case at the moment in the U.S. Supreme Court around the Myriad breast cancer gene that you might have heard about, and whatever way that's going to come down, the value of actually patenting a gene these days is very low. Most of it is in the public domain anyway, and more and more is going into the public domain. That's on one end of the spectrum, if you like.
The value, though, is going to be in the particular profile or genetic test or biomarker panel that you would like to put into a test that you or somebody will make and commercialize and sell. It's that value that needs to be protected with strong intellectual property, and that's being done in the genomics arena.
We have companies that have spun out of our projects. There is one looking at cancer gene panels for colorectal cancer. That's a commercialized product. It's available around the world, and the patenting was not on individual genes, but a panel of genes that was put together in a very innovative way.
I think we have the whole spectrum of activity, but toward the commercialization end, I think it's the specific use you're going to make of a specific panel that's based on your own innovation and your own discovery that's going to be of great value.